Foghorn Therapeutics (FHTX) Operating Income (2020 - 2025)
Historic Operating Income for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to -$18.5 million.
- Foghorn Therapeutics' Operating Income rose 2243.42% to -$18.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.5 million, marking a year-over-year increase of 1692.02%. This contributed to the annual value of -$102.7 million for FY2024, which is 484.03% up from last year.
- Foghorn Therapeutics' Operating Income amounted to -$18.5 million in Q3 2025, which was up 2243.42% from -$21.1 million recorded in Q2 2025.
- In the past 5 years, Foghorn Therapeutics' Operating Income registered a high of -$17.1 million during Q3 2023, and its lowest value of -$33.3 million during Q1 2023.
- Moreover, its 5-year median value for Operating Income was -$26.3 million (2021), whereas its average is -$25.8 million.
- As far as peak fluctuations go, Foghorn Therapeutics' Operating Income tumbled by 6853.69% in 2021, and later soared by 3955.55% in 2023.
- Quarter analysis of 5 years shows Foghorn Therapeutics' Operating Income stood at -$28.1 million in 2021, then decreased by 13.55% to -$31.9 million in 2022, then increased by 20.16% to -$25.5 million in 2023, then rose by 5.71% to -$24.0 million in 2024, then grew by 22.93% to -$18.5 million in 2025.
- Its last three reported values are -$18.5 million in Q3 2025, -$21.1 million for Q2 2025, and -$22.9 million during Q1 2025.